Baidu
map

高福院士团队新冠病毒重组蛋白亚单位疫苗启动Ⅲ期临床试验

2020-12-03 网络 网络

11月18日,中国科学院微生物研究所高福院士团队与重庆智飞生物制品股份有限公司(智飞生物)联合研制的新冠病毒重组蛋白亚单位疫苗,在湖南省湘潭市湘潭县开始国内部分的III期临床试验。

11月18日,中国科学院微生物研究所高福院士团队与重庆智飞生物制品股份有限公司(智飞生物)联合研制的新冠病毒重组蛋白亚单位疫苗,在湖南省湘潭市湘潭县开始国内部分的III期临床试验。

这项临床试验将在18周岁及以上人群中开展,采取随机、双盲、安慰剂对照的国际多中心临床试验,全球共计划招募29000人。而此项试验能够开展,主要是基于此前6月份开始在北京市、重庆市、湖南省三地相继开展的随机、双盲、安慰剂对照的I、II期临床试验。10月30日,该疫苗在中科院微生物所顺利完成Ⅰ/Ⅱ期临床试验揭盲,揭盲数据显示,临床试验结果符合预期,疫苗显示出了很好的安全性和免疫原性。

目前,中科院微生物所和智飞生物正积极推动该疫苗在乌兹别克斯坦、印度尼西亚、巴基斯坦、厄瓜多尔的III期临床试验。据了解,该疫苗由微生物所高福院士和严景华团队研发,戴连攀研究员是成果主要完成人之一,该疫苗拥有自主知识产权。是中国科技抗疫在疫苗研发领域并行推进的五条技术路线之一。

中科院微生物所介绍说,这次新冠病毒重组蛋白亚单位疫苗III期临床试验能够开展,主要是基于此前6月份开始在北京、重庆、湖南三地相继开展的随机、双盲、安慰剂对照的I、II期临床试验。10月底,该疫苗在中科院微生物所顺利完成Ⅰ/Ⅱ期临床试验揭盲,揭盲数据显示,临床试验结果符合预期,疫苗显示出很好的安全性和免疫原性。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=916018, encodeId=0306916018ab, content=学习到了知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/4904f1f58fd84759f4600a01d3817b4f.jpg, createdBy=f68b2548802, createdName=12539c47m51暂无昵称, createdTime=Tue Jan 12 20:22:44 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384708, encodeId=00da1384e086a, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495854, encodeId=56ef1495854e0, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904663, encodeId=aa57904663c5, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bc82893807, createdName=1804782854, createdTime=Thu Dec 03 20:36:28 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028842, encodeId=bbdc10288426d, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049265, encodeId=711110492654a, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=)]
    2021-01-12 12539c47m51暂无昵称

    学习到了知识

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=916018, encodeId=0306916018ab, content=学习到了知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/4904f1f58fd84759f4600a01d3817b4f.jpg, createdBy=f68b2548802, createdName=12539c47m51暂无昵称, createdTime=Tue Jan 12 20:22:44 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384708, encodeId=00da1384e086a, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495854, encodeId=56ef1495854e0, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904663, encodeId=aa57904663c5, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bc82893807, createdName=1804782854, createdTime=Thu Dec 03 20:36:28 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028842, encodeId=bbdc10288426d, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049265, encodeId=711110492654a, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=)]
    2020-12-05 xqptu
  3. [GetPortalCommentsPageByObjectIdResponse(id=916018, encodeId=0306916018ab, content=学习到了知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/4904f1f58fd84759f4600a01d3817b4f.jpg, createdBy=f68b2548802, createdName=12539c47m51暂无昵称, createdTime=Tue Jan 12 20:22:44 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384708, encodeId=00da1384e086a, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495854, encodeId=56ef1495854e0, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904663, encodeId=aa57904663c5, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bc82893807, createdName=1804782854, createdTime=Thu Dec 03 20:36:28 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028842, encodeId=bbdc10288426d, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049265, encodeId=711110492654a, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=916018, encodeId=0306916018ab, content=学习到了知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/4904f1f58fd84759f4600a01d3817b4f.jpg, createdBy=f68b2548802, createdName=12539c47m51暂无昵称, createdTime=Tue Jan 12 20:22:44 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384708, encodeId=00da1384e086a, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495854, encodeId=56ef1495854e0, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904663, encodeId=aa57904663c5, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bc82893807, createdName=1804782854, createdTime=Thu Dec 03 20:36:28 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028842, encodeId=bbdc10288426d, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049265, encodeId=711110492654a, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=)]
    2020-12-03 1804782854

    学习到了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=916018, encodeId=0306916018ab, content=学习到了知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/4904f1f58fd84759f4600a01d3817b4f.jpg, createdBy=f68b2548802, createdName=12539c47m51暂无昵称, createdTime=Tue Jan 12 20:22:44 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384708, encodeId=00da1384e086a, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495854, encodeId=56ef1495854e0, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904663, encodeId=aa57904663c5, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bc82893807, createdName=1804782854, createdTime=Thu Dec 03 20:36:28 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028842, encodeId=bbdc10288426d, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049265, encodeId=711110492654a, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=)]
    2020-12-03 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=916018, encodeId=0306916018ab, content=学习到了知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/4904f1f58fd84759f4600a01d3817b4f.jpg, createdBy=f68b2548802, createdName=12539c47m51暂无昵称, createdTime=Tue Jan 12 20:22:44 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384708, encodeId=00da1384e086a, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495854, encodeId=56ef1495854e0, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Sat Dec 05 06:46:51 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904663, encodeId=aa57904663c5, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bc82893807, createdName=1804782854, createdTime=Thu Dec 03 20:36:28 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028842, encodeId=bbdc10288426d, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049265, encodeId=711110492654a, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Thu Dec 03 18:46:51 CST 2020, time=2020-12-03, status=1, ipAttribution=)]
    2020-12-03 junJUN

    院士是学术至高点,也是大家必争之地呀

    0

相关资讯

高福委员呼吁:消除狂犬病,把疫苗打给狗

2月25日,“两会”到来之前一个普通的周一。国家卫生健康委员会召开例行发布会,邀请“两会”代表委员谈健康。据不完全统计,在我国卫生健康系统领域里有200多名“两会”代表委员。全国政协委员、中国科学院院士、中国疾控中心主任高福便是其中的一员。在发布会的提问过程中,记者将绝大部分问题抛给了他,发布结束时,他更是被一百多家媒体团团围住。

Science:热点:《科学》杂志专访高福院士:不戴口罩预防冠状病毒是一个“大错误”

近日,《科学》杂志通过短信、语音邮件和电话交谈采访了中国疾病预防控制中心(CDC)主任高福院士,为简洁明了起见,对本采访进行了编辑。

Sci Transl Med:高福院士揭示寨卡病毒治疗性抗体的机制

中科院微生物研究所严景华研究员与高福院士近期合作揭示高效、特异性人源寨卡病毒(zika virus, ZIKV)治疗性抗体及其机制。研发寨卡病毒治疗性抗体方面取得重要进展,率先找到高效、特异性人源寨卡病毒(zika virus, ZIKV)治疗性抗体及其机制,该抗体在小鼠模型上能有效治疗ZIKV感染,有望成为治疗其感染的候选药物。随着研究的深入,ZIKV的危害逐渐被揭示,从最初的发烧、皮疹等轻

Cell Rep:H4亚型禽流感病毒研究获进展

国科学院院士、中科院北京生命科学研究院副院长高福团队在H4亚型禽流感病毒适应人的分子机制和跨种间传播预警预测方面取得新的重要进展。研究结果以《H4亚型流感病毒血凝素蛋白从结合禽源到人源受体适应的分子基础》为题,于8月1日在线发表在国际学术期刊Cell Reports上

高福院士:艾滋病疫苗突破需要颠覆性思维

艾滋病正在逐渐变为一种可控的慢性疾病,但预防艾滋病的有效疫苗还未被人类开发出来。问及如何看待艾滋病疫苗的前景和发展方向时,中国疾病预防控制中心副主任、中国科学院院士高福表示:“艾滋病疫苗可能会解决,但是解决的方法一定不是现有的技术,需要完全是颠覆性的才可能解决。”

Nat Commun:高福院士揭示PD-1抗体作用的结构学机制

中科院微生物研究所严景华研究员与高福院士近期合作接连在Nature Communications,以及Science Translational Medicine杂志上发表文章,分别报道了nivolumab阻断PD-1/PD-L1 相互作用模式和PD-1蛋白糖基化修饰对其结合 nivolumab 的影响。

Baidu
map
Baidu
map
Baidu
map